News

Speakers at the 13th Annual Asthma & COPD Conference on March 29-30 in London, England will discuss the latest developments in asthma and chronic obstructive pulmonary disease (COPD). This year’s event will gather industry leaders, scientists, and members of the community to debate and talk about the latest challenges in asthma and COPD. The…

People with chronic obstructive pulmonary disease (COPD) often have other chronic conditions, like heart disease, and those who are poor about keeping  up with treatments for these comorbidites are also less likely to adhere to their COPD medications, according to results of a U.S. study conducted by Boehringer Ingelheim and Humana. The study,  “…

Early detectionof bronchiectasis among patients with chronic obstructive pulmonary disease (COPD) could lead to better disease management and, in the long run, better survival. But researchers do not agree on the best way to manage these patients, emphasizing the need for more research in patients with the two conditions. Researchers…

Sunovion Pharmaceuticals and Novartis have entered a commercialization agreement for three drugs approved by the U.S. Food and Drug Administration (FDA) indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Utibron Neohaler (indacaterol and glycopyrrolate) inhalation powder (27.5 mcg/15.6…

A sugar molecule called keratan sulfate could play a protective role against inflammation and emphysema associated with chronic obstructive pulmonary disease (COPD), according to a new study. The study, “A Keratan Sulfate Disaccharide Prevents Inflammation And The Progression Of Emphysema In Murine Models,” was published in the American…

The National Heart, Lung and Blood Institute (NHLBI) has named the recipient of its inaugural Outstanding Investigator Award: Yvonne Janssen-Heininger, PhD, professor of pathology and laboratory medicine at the Larner College of Medicine at the University of Vermont, to conduct studies on antioxidant therapies for lung diseases, including chronic obstructive pulmonary…

A protein called Wnt5a seems to be involved in the development of chronic obstructive pulmonary disease (COPD), according to a study published recently in the Journal of Experimental Medicine. This finding may be a path to the development of new therapies targeting this protein. The study was published under…

The chief executive of education for health and chair of the UK Inhaler Group, Monica Fletcher, will join a panel of speakers at the Asthma & COPD 2017 conference March 29-30 in London. Fletcher will discuss inhalers and patient compliance in the treatment of asthma and chronic obstructive…

Women who have never smoked are still vulnerable to develop chronic obstructive pulmonary disease (COPD). African-American women are especially susceptible to the disease, researchers at the University of Toronto found. The results of the study, “COPD in a Population-Based Sample of Never-Smokers: Interactions among Sex, Gender, and…

InMed Pharmaceuticals announced that its research and development program using cannabinoids for the treatment of chronic obstructive pulmonary disease (COPD) has made new progress. The company initiated its COPD program in June 2015, leveraging its bioinformatics analysis tool to identify the targets and potential active compounds that could be used…